Market Place
Sourcing Support
BioMarin: 4-Year ROCTAVIAN® Safety, Efficacy Data At Hemostasis Congress
07 Jun 2024 //
PR NEWSWIRE
BioMarin to Present ROCTAVIAN Data Highlighting Long-Term Durability
06 Feb 2024 //
PR NEWSWIRE
BioMarin First Person Treated Commercially with ROCTAVIAN Se.Hemophilia A in EU
30 Aug 2023 //
PR NEWSWIRE
Orsini Selected by BioMarin to Dispense ROCTAVIAN
11 Jul 2023 //
PR NEWSWIRE
US FDA approves BioMarin`s gene therapy for hemophilia A
30 Jun 2023 //
REUTERS
U.S. Food and Drug Administration Approves BioMarin`s ROCTAVIAN™
29 Jun 2023 //
PR NEWSWIRE
BioMarin wins approval for gene therapy to treat hemophilia A
29 Jun 2023 //
STAT NEWS
BioMarin to Present ROCTAVIAN Data from Hemophilia Gene Therapy Trial Program
22 Jun 2023 //
PRESS RELEASE
BioMarin gets first access deal in EU for gene therapy Roctavian
12 Jan 2023 //
PHARMAPHORUM
BioMarin Announces Advancements in FDA Review of ROCTAVIAN
24 Nov 2022 //
PRNEWSWIRE
BioMarin Announces Progress on BLA Review for Valoctocogene Roxaparvovec
07 Nov 2022 //
PRESS RELEASE
ICER Publishes Evidence Report on Gene Therapies for Hemophilia A and B
03 Nov 2022 //
ICER
FDA Accepts BioMarin`s BLA for Valoctocogene Roxaparvovec AAV Gene Therapy
12 Oct 2022 //
PRNEWSWIRE
BioMarin`s Gene Therapy for Adults with Severe Hemophilia A, ROCTAVIAN™
15 Sep 2022 //
PRESS RELEASE
BioMarin`s ROCTAVIAN gets EC approval as first gene therapy in Hemophilia A
25 Aug 2022 //
PRESS RELEASE
BioMarin`s hemophilia gene therapy wins conditional EU backing
25 Jun 2022 //
FIERCEPHARMA
BioMarin delays planned FDA filing for hemophilia gene therapy
01 Jun 2022 //
BIOPHARMADIVE
BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec
05 May 2022 //
PRNEWSWIRE
BioMarin`s Oral Presentation of 2-Year Analysis of Phase 3 Gene Therapy Study
04 Feb 2022 //
PRNEWSWIRE
BioMarin`s hemophilia A gene therapy hits goal in phase 3
11 Jan 2022 //
FIERCEBIOTECH
BioMarin Announces Updates from Phase 3 Gene Therapy Study in Hemophilia A
09 Jan 2022 //
PRNEWSWIRE
BioMarin Announces FDA RMAT Designation to Valoctocogene Roxaparvovec
08 Mar 2021 //
PRESS RELEASE
ICER Publishes Evidence Report on Therapies for Hemophilia A
16 Oct 2020 //
ICER
UPDATED: In another shocker, FDA rejects BioMarin’s hemophilia A gene therapy
19 Aug 2020 //
ENDPOINTSNEWS
#ISTH2020 – BioMarin’s Gene Therapy Drives Sustained FVIII Production
20 Jul 2020 //
HEMOPHILIANEWSTODAY
Investigational Gene Therapy Results in Huge Drop in Bleeding Rates VIII Usage
24 Jun 2020 //
HEMOPHILIANNEWSTODAY
BioMarin Provides Additional Data from Recent 4Y Ph1/2 Study of Valoctocogene
17 Jun 2020 //
PR NEWSWIRE
BioMarin Provides Highlights of 4 Y of Data from Ph1/2 Study of Valoctocogene
30 May 2020 //
PRNEWSWIRE
Ten drugs in pre-registration likely to be blockbusters by 2025, finds report
11 Mar 2020 //
EUROPEAN PHARMACEUTICALS
BioMarin`s BLA for Valoctocogene Roxaparvovec Accepted for Priority Review
20 Feb 2020 //
PR NEWSWIRE
EMA Validates BioMarin`s Marketing Authorization Application
21 Dec 2019 //
PR NEWSWIRE
BioMarin Submits BLA to FDA for Valoctocogene Roxaparvovec
21 Dec 2019 //
PR NEWSWIRE
BioMarin seeks European marketing approval for valoctocogene roxaparvovec
22 Nov 2019 //
PHARMABIZ
BioMarin Submits Marketing Authorization Application to EMA for Valoctocogene
21 Nov 2019 //
BIO SPACE
New data boost Pfizer, Sangamo hemophilia A gene therapy
08 Jul 2019 //
FIERCE BIOTECH
BioMarin eyes haemophilia therapy filing, but data scares investors
30 May 2019 //
PMLIVE
BioMarin Announces that Ph3 Cohort of Valoctocogene Roxaparvovec
28 May 2019 //
PR NEWSWIRE
